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Abstract
Background and Aims: Electrocardiography (ECG) is the most widely used initial screening test for the assessment of left
ventricular hypertrophy (LVH), an independent predictor of cardiovascular mortality in patients with end-stage renal disease
(ESRD). However, traditional ECG criteria based only on voltage to detect LVH have limited clinical utility for the detection of
LVH because of their poor sensitivity.
Methods: This prospective observational study was undertaken to compare the prognostic significance of commonly used
ECG criteria for LVH, namely Sokolow-Lyon voltage (SV) or voltage-duration product (SP) and Cornell voltage (CV) or
voltage-duration product (CP) criteria, and to investigate the association between echocardiographic LV mass index (LVMI)
and ECG-LVH criteria in ESRD patients, who consecutively started maintenance hemodialysis (HD) between January 2006
and December 2008.
Results: A total of 317 patients, who underwent both ECG and echocardiography, were included. Compared to SV and CV
criteria, SP and CP criteria, respectively, correlated more closely with LVMI. In addition, CP criteria provided the highest
positive predictive value for echocardiographic LVH. The 5-year cardiovascular survival rates were significantly lower in
patients with ECG-LVH by each criterion. In multivariate analyses, echocardiographic LVH [adjusted hazard ratio (HR): 11.71;
95% confidence interval (CI): 1.57–87.18; P=0.016] and ECG-LVH by SP (HR: 3.43; 95% CI: 1.32–8.92; P=0.011) and CP (HR:
3.07; 95% CI: 1.16–8.11; P=0.024) criteria, but not SV and CV criteria, were significantly associated with cardiovascular
mortality.
Conclusions: The product of QRS voltage and duration is helpful in identifying the presence of LVH and predicting
cardiovascular mortality in incident HD patients.
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Introduction
Cardiovascular disease is prevalent and the most common cause
of morbidity and mortality in patients with end-stage renal disease
(ESRD) [1]. Even though coronary artery disease and arrhythmia
are not uncommon, left ventricular hypertrophy (LVH) is the most
frequent cardiovascular manifestation in these patients [2,3]. LVH
is known to be present in more than 70% of incident ESRD
patients and increases the risk for cardiac ischemia and congestive
heart failure in patients on dialysis [4,5]. In addition, LVH is a
very strong independent predictor of cardiovascular mortality not
only among patients with hypertension but also among ESRD
patients [6–9].
LVH in ESRD patients is mainly attributed to hypertension and
anemia [10,11]. However, accumulating evidence shows that
volume overload, arteriovenous fistula, hyperparathyroidism, and
oxidative stress also play a role in the pathogenesis of LVH in
dialysis patients [12–15]. Moreover, LVH regression by modifying
these risk factors is associated with improved all-cause and
cardiovascular survival [7], while progression of LVH has
independent prognostic value for cardiovascular events in dialysis
patients [8]. Therefore, early identification of LVH and aggressive
treatment to regress LVH should become an important part of
management for ESRD patients.
To date, several imaging modalities, such as echocardiography,
magnetic resonance imaging (MRI), and computerized tomogra-
phy, have been performed to detect LVH [16–18]. In general,
however, electrocardiography (ECG) is more widely used for the
assessment of LVH [19]. ECG is a noninvasive, convenient,
inexpensive, and easily reproducible test, but the clinical utility of
traditional, purely voltage-based ECG criteria for the detection of
LVH is limited due to poor sensitivity [20]. Therefore, criteria
based on the combination of voltage and QRS duration have been
developed and have improved the sensitivity for LVH in the
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elucidated the relationship between LVH based on different
electrocardiographic criteria and echocardiographic LVH [23].
Moreover, a very recent study demonstrated the impact of LVH
determined by different ECG criteria on clinical outcome in
chronic kidney disease [24]. However, little is known about the
association between electrocardiographic and echocardiographic
LVH in patients with CKD and ESRD. Furthermore, no study
has explored whether the prognostic power of ECG varies in
ESRD patients based on the diagnostic criteria for LVH. In this
prospective study, therefore, we compared commonly used ECG
criteria for LVH to ascertain their prognostic significance and
investigated the association between echocardiographic LV mass
and ECG-LVH criteria in incident hemodialysis (HD) patients.
Methods
Ethics statement
The study was carried out in accordance with the Declaration of
Helsinki and approved by the Institutional Review Board of
Yonsei University Health System Clinical Trial Center. We
obtained informed written consent from all participants involved
in our study.
Patients
For this prospective observational study, we initially recruited a
total of 603 patients who consecutively started maintenance HD at
Yonsei University Health System, Seoul, Korea, between January
2006 and December 2008 and were regularly followed-up at the
outpatient clinic. Echocardiography was not performed in 35
patients due to noncompliance or other personal reasons, and in
44 patients it was undergone before the initiation of HD. Of these
patients, 207 patients were also excluded for the following reasons:
age ,18 years (n=4) or .75 years (n=11), previous history of
peritoneal dialysis or kidney transplantation before HD (n=139),
severe systolic dysfunction (ejection fraction ,30%, n=7), severe
valvular heart disease (n=11), underlying malignancy (n=21),
decompensated liver cirrhosis (n=3), complete bundle branch
block (n=9), and pacemaker insertion (n=2). Thus, a total of 317
patients were included in the final analysis.
Data collection
Demographic and clinical data at the time of HD initiation,
including age, gender, and comorbidities, were recorded. The
results of the following laboratory tests performed at the same time
were also collected: hemoglobin, serum albumin, total cholesterol,
calcium, phosphate, and high-sensitivity C-reactive protein levels.
The single-pool Kt/V in HD patients was measured with standard
Gotch equations on the mid-dialysis day near at the time of
discharge [25].
ECG
Upon admission, a standard 12-lead electrocardiogram was
recorded using a MAC 5500 machine (GE Medical system,
Milwaukee, WI, USA). All of the patients underwent an additional
ECG on a nondialysis day, within 24 hours after the last HD and
near the time of discharge, and this follow-up ECG was used for
analysis. The output from the MAC 5500 provided QRS duration,
PR interval, QT interval, and axes in an automated fashion, but
not QRS voltage of every lead. Thus, two independent technicians
measured the voltage and discrepancies of .2 mm were resolved
by a third reader. The cut-off point for LVH by Sokolow-Lyon
voltage (RV5/6+SV1) was $35 mm and by Cornell voltage
(RaVL+SV3) was $28 mm in men and $20 mm in women [21].
Products of QRS duration multiplied by the Cornell voltage
combination (with 6 mm added in women) $2440 mmNmsec and
by the Sokolow-Lyon voltage combination $3674 mmNmsec in
men and $3224 mmNmsec in women were used to determine
LVH [22]. The QTc interval was calculated based on Bazett’s
formula: QTc interval=QT/!RR, and the following criteria were
used to determine QTc interval prolongation: QTc$460 msec in
women; QTc$450 msec in men [26].
Echocardiography
Echocardiography was performed at the time of follow-up ECG
based on the imaging protocol recommended by the American
Society of Echocardiography using a SONOS 7500 (Philips
Ultrasound, Bothell, WA, USA). LV systolic function was defined
by LV ejection fraction (LVEF) using a modified biplane
Simpson’s method from the apical two- and four-chamber views.
LV mass (LVM) was determined using the method described by
Devereux and Reichek [27], and LV mass index (LVMI) was
calculated by dividing LVM by body surface area (BSA).
Echocardiographic LVH was defined as a LVMI.131 g/m
2 for
men and .100 g/m
2 for women [28]. Hypertrophy was
considered concentric if LV relative wall thickness was .0.43,
and patients with normal LV mass were considered to have
normal LV geometry if relative wall thickness was #0.43 or to
have concentric remodeling if relative wall thickness was increased
[23]. Left atrial volume was assessed by the biplane area-length
method from the apical two- and four-chamber views and was
indexed for BSA. Mitral inflow was assessed with Doppler
echocardiography from the apical four-chamber view, and pulse-
wave tissue Doppler imaging of the septal mitral annulus was also
obtained from the apical four-chamber view. Systolic RV pressure
was calculated using the modified Bernoulli equation [46(tricuspid
systolic jet)
2+10 mmHg].
Outcome measures
All the patients included in this study were followed-up every 3
months at the outpatient clinic, and all deaths and hospitalizations
were recorded in the serious adverse events database. For this
study, the mortality events were retrieved from the database and
carefully reviewed. Cardiovascular mortality, the primary study
endpoint, was considered to be death from myocardial infarction
or ischemia, congestive heart failure, pulmonary edema, and
cerebral hemorrhage or vascular disorder.
Statistical analysis
Statistical analysis was performed using SPSS version 18.0
(SPSS Inc, Chicago, IL, USA). Continuous variables were
expressed as mean 6 SD, and categorical variables as percentages.
To determine differences between the two groups, Student’s t-test
or Mann-Whitney U test was used for continuous variables and
the chi-square test was used for categorical variables. Pearson’s
correlation analysis was performed to estimate the association
between LVMI and ECG criteria measurements. Cumulative
survival curves were generated by the Kaplan-Meier method, and
between-group survival was compared by a log-rank test. The
independent prognostic values of electrocardiographic and
echocardiographic LVH for cardiovascular mortality were ascer-
tained by Cox proportional hazards regression analysis, which
included only the significant variables in univariate analysis.
Factors of specific interest were also included in another
multivariate analysis. However, each ECG-LVH or echocardio-
graphic criterion was entered separately because there was a
significant interaction with each other. The hazard ratios (HRs)
and 95% confidence intervals (CIs) were calculated using the
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predictive values for echocardiographic LVH and cardiovascular
mortality were also analyzed by receiver operating characteristic
(ROC) curve analysis with calculated area under the ROC curve
(AUC). The correlation coefficients between LVMI and each
ECG criterion measurements and the AUC of each ECG-LVH
criterion for echocardiographic LVH and cardiovascular mortality
were compared using a two-tailed Z-score. P-values less than 0.05
were considered statistically significant.
Results
Clinical and biochemical characteristics
The baseline patient characteristics according to the presence
ECG-LVH are shown in Table 1. The mean age was 56.7614.2
years (range: 18–75 years), and 53.6% were male. Of the 317
patients, LVH was present in 60 patients (18.9%) by Sokolow-
Lyon voltage (SV), 43 (13.6%) by Sokolow-Lyon voltage-duration
product (SP), 38 (12.0%) by Cornell voltage (CV), and 43 (13.6%)
by Cornell voltage-duration product (CP) criteria. The proportion
of male patients was significantly higher in the ECG-LVH group
Table 1. Clinical and biochemical characteristics according to the presence or absence of electrocardiographic LVH.
Sokolow-Lyon voltage LVH Sokolow-Lyon product LVH Cornell voltage LVH Cornell product LVH
No (n=257)
Yes
(n=60) P No (n=274)
Yes
(n=43) P No (n=279)
Yes
(n=38) P No (n=274)Yes (n=43)P
Age (years) 56.4614.3 58.3613.8 0.36 56.0614.2 61.5613.0 0.018 56.6614.4 58.0612.1 0.57 56.5614.4 58.4612.6 0.42
Male gender 130 (51%) 40 (67%) 0.024 144 (53%) 26 (61%) 0.33 152 (54%) 22 (58%) 0.40 144 (53%) 26 (61%) 0.33
Diabetes 143 (56%) 31 (52%) 0.58 149 (54%) 25 (58%) 0.65 151 (54%) 23 (61%) 0.46 148 (54%) 26 (61%) 0.43
Hypertension 227 (88%) 54 (90%) 0.71 239 (87%) 42 (98%) 0.045 245 (88%) 36 (95%) 0.21 240 (88%) 41 (95%) 0.14
Coronary artery disease 39 (15%) 15 (25%) 0.07 44 (16%) 10 (23%) 0.24 46 (17%) 8 (21%) 0.48 41 (15%) 13 (30%) 0.01
History of smoking 36 (14%) 12 (20%) 0.24 40 (15%) 8 (19%) 0.50 43 (15%) 5 (13%) 0.72 40 (15%) 8 (19%) 0.50
Primary renal disease 0.54 0.77 0.88 0.52
Diabetes 143 (56%) 30 (50%) 149 (54%) 24 (56%) 150 (54%) 23 (61%) 147 (54%) 26 (61%)
Glomerulonephritis 24 (9%) 4 (7%) 26 (10%) 2 (5%) 25 (9%) 3 (8%) 24 (9%) 4 (9%)
ADPKD 7 (3%) 1 (2%) 7 (3%) 1 (2%) 7 (3%) 1 (3%) 6 (2%) 2 (5%)
Others 83 (32%) 25 (42%) 92 (34%) 16 (37%) 97 (35%) 11 (29%) 97 (35%) 11 (26%)
Body mass index (kg/m
2) 23.863.4 22.563.1 0.008 23.763.4 22.863.2 0.11 23.763.5 22.862.5 0.12 23.663.4 22.963.4 0.20
MBP (mmHg) 99.0614.2 100.5614.40.48 99.1614.3 100.8613.90.47 98.8614.0 103.2615.30.08 99.3614.1 99.4614.9 0.97
Heart rate (bpm) 73.5613.5 75.0613.5 0.44 74.1613.6 72.4612.8 0.46 73.7613.7 75.0612.6 0.58 74.1613.4 72.3614.1 0.42
Blood urea nitrogen (mg/dl) 93.7632.1 93.4628.8 0.95 93.3631.2 95.7633.3 0.64 94.3632.2 88.9625.8 0.32 93.1631.4 97.2632.3 0.42
Creatinine (mg/dl) 9.864.7 9.964.2 0.86 9.864.6 9.764.3 0.92 9.964.7 9.163.5 0.32 9.764.7 10.264.1 0.55
eGFR (ml/min/1.73 m
2)6 . 5 63.0 6.362.4 0.71 6.563.0 6.362.5 0.73 6.562.9 6.462.7 0.82 6.563.0 6.162.6 0.37
Calcium (mg/dl) 7.861.1 8.061.1 0.18 7.861.1 8.061.1 0.18 7.861.1 8.160.9 0.07 7.861.1 7.961.2 0.56
Phosphate (mg/dl) 6.261.9 6.361.7 0.85 6.261.9 6.361.8 0.78 6.261.9 6.161.9 0.80 6.261.8 6.562.1 0.32
Albumin (g/dl) 3.560.7 3.660.6 0.33 3.560.7 3.660.5 0.33 3.560.7 3.460.6 0.26 3.560.7 3.560.6 0.95
Cholesterol (mg/dl) 161.9650.0 155.3641.20.34 161.3649.3 157.0643.10.60 159.0648.2 173.0648.80.10 160.1649.0 164.2645.1 0.61
Hemoglobin (g/dl) 8.461.6 8.661.3 0.56 8.461.6 8.761.4 0.34 8.461.6 8.861.5 0.16 8.461.6 8.661.6 0.55
C-reactive protein (mg/l) 0.860.9 1.161.5 0.18 0.861.1 0.861.0 0.91 0.861.1 0.860.9 0.88 0.861.1 1.061.2 0.40
Single-pool Kt/V 1.360.3 1.260.3 0.76 1.160.4 1.260.3 0.79 1.260.4 1.360.3 0.71 1.260.3 1.360.3 0.81
No of antihypertensive drugs 2.161.2 2.261.2 0.55 2.161.2 2.161.1 0.89 2.161.2 2.461.1 0.13 2.161.2 2.261.0 0.79
Antihypertensive drugs
b-blockers 144 (56%) 30 (50%) 0.40 151 (55%) 23 (54%) 0.84 152 (55%) 22 (58%) 0.69 152 (56%) 22 (51%) 0.60
ACE inhibitors or ARBs 148 (58%) 39 (65%) 0.29 160 (58%) 27 (63%) 0.59 158 (57%) 29 (76%) 0.02 159 (58%) 28 (65%) 0.38
Calcium channel blockers 191 (74%) 47 (78%) 0.52 205 (75%) 33 (77%) 0.79 206 (74%) 32 (84%) 0.17 203 (74%) 35 (81%) 0.30
Statin use 74 (29%) 17 (28%) 0.94 74 (27%) 17 (40%) 0.09 77 (28%) 14 (37%) 0.24 72 (26%) 19 (44%) 0.02
Coronary revasculization 31 (12%) 16 (27%) 0.004 31 (11%) 16 (37%) ,0.001 37 (13%) 10 (26%) 0.03 33 (12%) 14 (33%) ,0.001
Stroke 16 (6%) 7 (12%) 0.14 20 (7%) 3 (7%) 0.94 19 (7%) 4 (11%) 0.41 19 (7%) 4 (9%) 0.58
ADPKD, autosomal dominant polycystic kidney disease; MBP, mean arterial blood pressure; BPM, beat per minute; eGFR, estimated glomerular filtration rate; No,
number; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; LVH, left ventricular hypertrophy.
Data are presented as n (%) or mean 6 SD.
doi:10.1371/journal.pone.0035534.t001
Electrocardiographic LVH in Hemodialysis Patients
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35534by SV criteria, whereas the proportion of patients with
hypertension was significantly higher in the ECG-LVH group by
SP criteria (P,0.05). In addition, there was a significant difference
in body mass index (BMI) between patients with and without
ECG-LVH only by SV criteria (22.563.1 vs. 23.863.4 kg/m
2,
P=0.008). Moreover, patients with ECG-LVH by CP criteria
showed a significantly higher prevalence of coronary artery disease
(P,0.05). A history of coronary revascularization was significantly
more prevalent in patients with ECG-LVH by each criterion than
in those without ECG-LVH (P,0.05). Blood urea nitrogen,
creatinine, albumin, and cholesterol concentrations and Kt/V
were also comparable between patients with and without ECG-
LVH by each criterion.
Echocardiographic and electrocardiographic findings
As shown in Table 2, LV mass index (LVMI) and left atrial
volume index were significantly higher, while LV ejection fraction
was significantly lower in patients with LVH by each criterion
compared to those without ECG-LVH. In addition, the early
mitral inflow velocity to peak mitral annulus velocity (E/E’) ratio
was significantly higher only in patients with ECG-LVH by QRS
voltage-duration product criteria. On the other hand, QT interval
was significantly prolonged in patients with ECG-LVH based on
SP and CP criteria than in those without ECG-LVH by these
criteria.
Pearson’s correlation analysis revealed that SP (r=0.357,
P,0.001) and CP (r=0.410, P,0.001) criteria seemed to
correlate more closely with LVMI compared to SV (r=0.319,
P,0.001) and CV (r=0.388, P,0.001) criteria, respectively, but
the differences did not reach statistical significance (SP vs. SV, Z
statistic=0.542, P=0.59; CP vs. CV, Z statistic=0.172, P=0.86)
(Figure 1). The positive predictive values of SP (86.0%) and CP
(89.5%) for echocardiographic LVH were also higher relative to
those of SV (81.7%) and CV (86.0%). Among the four ECG
criteria, moreover, the CP criteria provided the highest predictive
value for echocardiographic LVH in ROC curve analysis
(AUC=0.657, P,0.001) (Figure 2). Furthermore, the AUC of
the CP criteria was significantly greater than those of the other
three ECG-LVH criteria (CP vs. CV, Z statistic=4.793, P,0.001;
CP vs. SP, Z statistic=2.707, P=0.007; CP vs. SV, Z
statistic=2.146, P=0.032).
Table 2. Echocardiographic and electrocardiographic parameters according to the presence or absence of echocardiographic LVH.
Sokolow-Lyon voltage
LVH Sokolow-Lyon product LVH Cornell voltage LVH Cornell product LVH
No
(n=257)
Yes
(n=60) P
No
(n=274)
Yes
(n=43) P
No
(n=279)
Yes
(n=38) P
No
(n=274)
Yes
(n=43) P
Echocardiography
Ejection fraction (%) 62.2610.1 57.8610.5 0.003 62.0610.0 57.0611.6 0.003 61.8610.0 58.4612.1 0.05 62.369.7 55.7612.1 0.001
LVEDD (mm) 51.565.2 53.565.5 0.011 51.565.0 54.466.3 0.001 51.865.0 52.967.2 0.34 51.565.0 54.366.7 0.01
IVS thickness (mm) 10.761.8 11.661.7 ,0.001 10.861.8 11.761.6 0.001 10.861.7 11.962.2 ,0.001 10.761.7 12.062.1 ,0.001
PW thickness (mm) 10.661.6 11.561.6 0.001 10.761.7 11.561.5 0.004 10.761.6 11.761.6 0.001 10.661.6 11.861.4 ,0.001
LV mass index (g/m
2)1 2 7 . 3 627.7145.0626.3,0.001 127.7627.2 149.7627.9,0.001 128.1627.5149.5626.9 ,0.001 127.2627.0152.6626.7 ,0.001
LA volume index (ml/m
2)3 4 . 6 6 12.2 40.8612.7 ,0.001 34.6612.0 43.6613.0 ,0.001 35.2612.4 39.8612.5 0.032 34.9612.2 41.2613.0 0.002
RV pressure (mmHg) 31.7610.6 33.4611.2 0.28 31.7610.4 34.0612.2 0.22 31.8610.8 33.8610.1 0.31 31.6610.4 34.5612.1 0.12
E/E’ratio 16.667.1 18.168.0 0.17 16.566.9 19.669.1 0.046 16.366.9 21.168.1 ,0.001 16.466.7 19.869.6 0.033
Echocardiographic LVH 169 (54%) 49 (60%) 0.017 181 (53%) 37 (65%) 0.009 184 (53%) 34 (69%) 0.003 181 (53%) 37 (70%) 0.009
Relative wall thickness 0.4260.08 0.4360.07 0.18 0.4260.08 0.4360.07 0.59 0.4260.07 0.4560.10 0.12 0.4260.08 0.4460.08 0.05
Concentric remodeling/LVH 105 (41%) 31 (52%) 0.13 113 (41%) 23 (53%) 0.13 113 (41%) 23 (61%) 0.019 112 (41%) 24 (56%) 0.07
Electrocardiography
PR interval (msec) 168.5630.6163.8625.40.28 167.4630.1 169.2627.30.73 168.7630.1160.3625.6 0.11 167.0628.9171.9634.3 0.33
QRS duration (msec) 93.0614.7 94.0611.2 0.63 91.4611.9 104.7620.4,0.001 93.0614.2 94.6613.2 0.50 91.3613.4 105.1612.6 ,0.001
QTc interval (msec) 458.0635.6467.0640.80.12 457.3635.7 475.1639.70.003 458.8635.2466.6646.1 0.22 457.1633.3476.5650.9 0.019
ST-T abnormalities 17 (7%) 13 (22%) ,0.001 16 (6%) 14 (33%) ,0.001 15 (5%) 15 (40%) ,0.001 12 (4%) 18 (42%) ,0.001
Sokolow-Lyon voltage (mm) 23.866.3 41.365.4 ,0.001 24.867.1 42.066.8 ,0.001 26.368.6 33.3611.0 0.001 26.068.5 34.3610.6 ,0.001
Sokolow-Lyon voltage LVH - - - 24 (9%) 36 (84%) ,0.001 42 (15%) 18 (47%) ,0.001 40 (15%) 20 (47%) ,0.001
Sokolow-Lyon product 22256743 38886759 ,0.001 22606694 43226695 ,0.001 24506914 319461264 0.001 23766862 358361121 ,0.001
Sokolow-Lyon product LVH 7 (3%) 36 (60%) ,0.001 - - - 28 (10%) 15 (40%) ,0.001 23 (8%) 20 (47%) ,0.001
Cornell voltage (mm) 15.065.5 21.967.1 ,0.001 15.465.6 21.668.5 ,0.001 14.865.1 26.965.2 ,0.001 14.664.8 26.865.3 ,0.001
Cornell voltage LVH 20 (8%) 18 (30%) ,0.001 23 (8%) 15 (35%) ,0.001 - - - 13 (5%) 25 (58%) ,0.001
Cornell product 16606553 22706848 ,0.001 16686531 24586960 ,0.001 16186480 29316679 ,0.001 15776423 30366510 ,0.001
Cornell product LVH 23 (9%) 20 (33%) ,0.001 23 (8%) 20 (47%) ,0.001 18 (7%) 25 (66%) ,0.001 - - -
LV, left ventricle; IVS, interventricular septum; PW, posterior wall; LA, left atrium; RV, right ventricle; E/E’, ratio of early mitral inflow velocity to peak mitral annulus
velocity; LVH, left ventricular hypertrophy.
Data are presented as mean 6 SD.
doi:10.1371/journal.pone.0035534.t002
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During the mean follow-up duration of 27.4617.2 months (3.0–
64.0 months), 41 patients (12.9%) died over 725 patient-years of
cumulative follow-up, yielding a crude mortality rate of 5.66/100
patient-years. Among them, 25 patients (7.9%) died from
cardiovascular causes. Patients with echocardiographic LVH had
a significantly lower cardiovascular mortality-free survival than
those without echocardiographic LVH (72.2% vs. 98.0%,
P=0.003). In addition, the 5-year cardiovascular survival rates
were significantly lower in patients with ECG-LVH by SV (60.7%
vs. 88.1%, P=0.026), SP (50.6% vs. 87.6%, P=0.001), CV
(56.2% vs. 87.0%, P=0.017), and CP criteria (55.7% vs. 87.7%,
P=0.001) (Figure 3). Moreover, patients with ST-T wave
abnormalities secondary to LVH, including a horizontal or
downsloping ST segment and T wave inversion, showed
significantly lower cardiovascular survival rates compared to those
without these findings (39.5% vs. 87.3%, P=0.005). However,
there was no significant difference in cardiovascular mortality
between patients with concentric and eccentric LVH and between
patients with and without QTc interval prolongation. The overall
mortality was also comparable between patients with and without
echocardiographic LVH or ECG-LVH.
Table 3 shows the hazard ratios (HRs) for cardiovascular
mortality according to the presence of echocardiographic or
electrocardiographic LVH. In an unadjusted Cox regression
model, there was a significant increased risk for cardiovascular
mortality in patients with echocardiographic LVH and ECG-LVH
by each criterion. In multivariate analysis adjusted for age,
diabetes, and coronary artery disease, which were revealed as
significant independent predictors of cardiovascular mortality in
univariate analysis, echocardiographic LVH and ECG-LVH
based on QRS voltage-duration product were still significantly
associated with cardiovascular mortality, but the significant
association between ECG-LVH by purely voltage-based criteria
and cardiovascular mortality in the unadjusted model disappeared
(Model 1). Moreover, even when factors of specific interest, such as
ejection fraction, ST-T wave changes, and QTc interval, were
included in a multivariate model, echocardiographic LVH (HR:
11.71; 95% CI: 1.57–87.18; P=0.016) and ECG-LVH by SP
(HR: 3.43; 95% CI: 1.32–8.92; P=0.011) and CP (HR: 3.07; 95%
CI: 1.16–8.11; P=0.024) criteria, but not SV and CV criteria,
were significantly associated with cardiovascular mortality (Model
2). In ROC curve analysis, CP criteria provided the highest
predictive value for cardiovascular mortality (AUC=0.720,
P,0.001), but there were no statistical differences in the AUC
among the four ECG-LVH criteria (Figure 4).
Figure 1. Correlation between electrocardiographic LVH and left ventricular mass index (LVMI). (A) Sokolow-Lyon voltage (SV), Cornell
voltage (CV), (B) Sokolow-Lyon voltage-duration product (SP), and Cornell voltage-duration product (CP) correlated significantly with LVMI. Data are
correlation coefficients (r).
doi:10.1371/journal.pone.0035534.g001
Figure 2. ROC curve analysis for echocardiographic LVH. The
ROC curve was constructed by plotting the sensitivity (true positive
rate) vs. 1-specificity (false positive rate) for each ECG-LVH criterion. At
the highest predicted probability, sensitivities of Sokolow-Lyon voltage
(SV), Sokolow-Lyon voltage-duration product (SP), Cornell voltage (CV),
and Cornell voltage-duration product (CP) were 27.1%, 40.8%, 32.6%,
and 45.9%, respectively.
doi:10.1371/journal.pone.0035534.g002
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In ESRD patients, LVH detected by ECG or echocardiography
is the most common manifestation of cardiovascular disease and
strongly predicts cardiovascular morbidity and mortality [2,3,7–9].
In this study, we demonstrate that SP and CP criteria correlated
more closely with LVMI determined by echocardiography
compared to SV and CV criteria, respectively, and that CP
criteria provide the highest predictive value for identification of
LVH. In addition, LVH based on QRS voltage-duration product
is an independent predictor of cardiovascular mortality in incident
HD patients, whereas LVH by QRS voltage-based criteria is not.
Prevalence of LVH
LVH is prevalent in patients with CKD and its prevalence is
known to increase as eGFR decreases [4,5,29,30]. However,
previous studies show wide variation in the prevalence of LVH in
CKD and ESRD patients. A very recent study revealed that the
prevalence of ECG-LVH by the Sokolow-Lyon criteria was 10%
and by Cornell criteria was 14% in patients with CKD [24].
However, in a Spanish multicenter study on hypertensive patients,
more than 20% of the subjects with CKD had ECG-LVH by
Cornell criteria [22]. Meanwhile, Foley et al. demonstrated that
LVH by echocardiography was present in 74% of ESRD patients
at the start of dialysis [4], whereas Levin et al. found the overall
prevalence of echocardiographic LVH to be 36% of ESRD
patients [5]. In the 4D study, even though all patients were ESRD
patients on hemodialysis and had type 2 diabetes, only 12.4% had
EKG-LVH by Sokolow-Lyon criteria [31]. The results of the
present study also revealed wide variation in the prevalence of
LVH: 18.9% by SV, 13.6% by SP, 12.0% by CV, 13.6% by CP
criteria, and 68.8% by echocardiography. We surmise that these
discrepancies in the prevalence of LVH can be attributed to
differences in patient age, gender, ethnicity, BMI, hemoglobin
levels, and residual renal function and the proportion of patients
with hypertension. Particularly, obesity has been shown to
decrease the sensitivity of precordial lead ECG criteria, especially
SV criteria, for the identification of LVH because QRS
amplitudes are attenuated by interposed tissue, which increases
the distance of exploring electrodes from LV [32]. In our study,
the prevalence of ECG-LVH by SV criteria might in part be
influenced by a relatively low BMI of the subjects, and the
Figure 3. Kaplan-Meier curves for cardiovascular survival. Compared to patients without electrocardiographic LVH, the 5-year cardiovascular
survival rates were significantly lower in patients with electrocardiographic LVH based on (A) Sokolow-Lyon voltage (SV), (B) Sokolow-Lyon voltage-
duration product (SP), (C) Cornell voltage (CV), and (D) Cornell voltage-duration product criteria (CP).
doi:10.1371/journal.pone.0035534.g003
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gender-based. Whether LVH was assessed by echocardiography
or ECG and which ECG criteria were used to define LVH may
contribute to this wide variation in the prevalence of LVH.
LVH and cardiovascular outcomes
Mounting evidence indicates that LVH is a powerful indepen-
dent predictor of cardiovascular mortality in patients with CKD
and ESRD [9]. Moreover, the change in LVH has been
demonstrated as a strong prognostic factor in these patients. A
previous prospective study on prevalent HD patients revealed that
the rates of LVMI increase were significantly higher in patients
with incident cardiovascular events than in those without such
events, and that cardiovascular event-free survival in patients with
changes in LVMI below the 25th percentile was significantly
higher than in those with changes above the 75th percentile [8].
Similarly, in a cohort study of 153 incident ESRD patients
receiving HD, a 10% reduction in LVM during a mean follow-up
duration of 54 months resulted in a 22% decrease in all-cause
mortality and a 28% decrease in cardiovascular mortality [7].
Furthermore, in that study, LVM regression was independently
associated with improved patient survival even after adjustment for
age, gender, diabetes, history of cardiovascular disease, and all
nonspecific cardiovascular risk factors. While these two studies
used echocardiography to assess LVMI or LVM as an indicator of
LVH, similar results were observed in hypertensive patients with
ECG-LVH [33,34]. With a median interval of 23 days, persistent
ECG-LVH at baseline and follow-up identified patients with
greater LVM and a higher prevalence of echocardiographic LVH,
suggesting that these patients may be at higher risk for subsequent
morbidity and mortality [23]. We did not clarify the impact of the
changes in LVM or LVMI by echocardiography, newly developed
ECG-LVH, and the regression or persistence of ECG-LVH on
patients’ outcome. Nevertheless, consistent with most previous
studies, the baseline echocardiographic LVH at the time of HD
initiation was found to be significantly associated with worse
cardiovascular survival in incident ESRD patients.
ECG for the detection of LVH
ECG is a simple tool for the detection of LVH and is widely
used in clinical setting [19]. According to the Kidney Disease
Outcome Quality Initiative (K/DOQI) practice guidelines,
recording of an ECG is recommended in every patient at the
initiation of renal replacement therapy and yearly thereafter [35].
Due to the relatively low sensitivity of traditional ECG criteria for
the detection of LVH, however, the clinical utility of ECG is
limited [20]. On the other hand, prolongation of QRS duration is
often observed in patients with LVH [36]. In addition, QRS
duration was demonstrated to correlate with LVM [21]. Even
though the mechanism for QRS prolongation in LVH has not
been clearly determined, it may be related to a longer time
required to activate myocardium, decreased conduction velocity in
hypertrophic myocardium, and changes in activation sequence or
in the relative conductivity of fibrotic intracellular and extracel-
lular spaces [21]. In fact, the VIPE study, which evaluated the
effect of candesartan-based treatment on LVH in hypertensive
patients, demonstrated that candesartan treatment for 6 months
not only reduced LVM, but also shortened the QRS duration
[37]. Nevertheless, QRS duration alone has been proven to be
poorly sensitive at clinically relevant levels of specificity [36]. For
these reasons, there have been many attempts to increase the
sensitivity of ECG for the identification of LVH by combining the
voltage criteria with QRS duration, and these efforts have
modestly improved the performance of ECG for detecting LVH
Figure 4. ROC curve analysis for cardiovascular mortality. The
ROC curve was constructed by plotting the sensitivity (true positive
rate) vs. 1-specificity (false positive rate) for each ECG-LVH criterion. At
the highest predicted probability, sensitivities of Sokolow-Lyon voltage
(SV), Sokolow-Lyon voltage-duration product (SP), Cornell voltage (CV),
and Cornell voltage-duration product (CP) were 68.1%, 72.3%, 64.2%,
and 76.0%, respectively.
doi:10.1371/journal.pone.0035534.g004
Table 3. Cox regression models for cardiovascular mortality.
unadjusted Model 1 Model 2
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Echocardiographic LVH 10.88 (1.47–80.43) 0.019 9.11 (1.22–67.82) 0.031 11.71 (1.57–87.18) 0.016
Sokolow-Lyon voltage LVH 2.42 (1.08–5.42) 0.031 1.68 (0.71–3.97) 0.24 2.00 (0.86–4.68) 0.11
Sokolow-Lyon product LVH 3.75 (1.64–8.53) 0.002 2.80 (1.19–6.54) 0.018 3.43 (1.32–8.92) 0.011
Cornell voltage LVH 2.70 (1.16–6.31) 0.022 2.25 (0.95–5.30) 0.06 1.84 (0.68–4.97) 0.23
Cornell product LVH 3.69 (1.65–8.25) 0.001 2.64 (1.14–6.13) 0.024 3.07 (1.16–8.11) 0.024
Data are reported as hazard ratio (HR) and 95% confidence interval (CI).
Model 1: Adjusted for age, diabetes, and coronary artery disease.
Model 2: Adjusted for ejection fraction, ST-T wave abnormalities, and QTc interval.
doi:10.1371/journal.pone.0035534.t003
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However, most previous studies on CKD or ESRD patients used
voltage criteria to determine ECG-LVH and did not validate
ECG-LVH criteria for clinical outcomes [31]. Moreover, few
studies have explored the relationship between electrocardio-
graphic and echocardiographic LVH. In this study, we tried to
elucidate the correlation between commonly used criteria of ECG-
LVH and echocardiographic LVH, and found that SP and CP
criteria correlated more closely with LVMI determined by
echocardiography than SV and CV criteria, respectively and that
CP criteria provided the highest predictive value for echocardio-
graphic LVH. Furthermore, besides echocardiographic LVH,
ECG-LVH only by SP and CP criteria was an independent risk
factor for cardiovascular mortality in incident HD patients. These
findings suggest that the considering QRS duration in addition to
voltage may not only improve the identification of LVH but also
serve as a more significant predictor of cardiovascular outcome in
ESRD patients.
Echocardiography for the detection of LVH
Echocardiography is a noninvasive procedure and provides an
accurate assessment of ventricular size, geometry, and function.
However, in ESRD patients, echocardiographic measurements,
particularly of LVM, are highly dependent on the timing of
echocardiography in relationship to dialysis sessions and to
intravascular volume [38]. In addition, compared to MRI,
echocardiography is known to significantly overestimate LVM in
HD patients when LVH and dilation are present [17]. Moreover,
the intra-observer and inter-observer variability of echocardiog-
raphy are significantly higher than those of MRI. Nevertheless,
MRI is not routinely performed because it is not widely available,
is expensive, and cannot be used in patients with cardiac
implantable devices. Consistent with most clinical and research
studies, we used LVMI by echocardiography to determine LVH.
Furthermore, since the ability to detect LVH in HD patients is
improved by performing echocardiography on a nondialysis day,
preferably between 12 and 18 hours after the last dialysis session,
patients included in the present study underwent echocardiogra-
phy on a nondialysis day, within 24 hours after the last dialysis,
and near the time of discharge to minimize the volume effect on
echocardiographic parameters.
Limitations
Our study has several limitations. First, since the study subjects
were all Korean ESRD patients on HD, the association between
EKG-LVH criteria and clinical outcomes may not be generaliz-
able to other populations. In addition, even though the number of
patients was small (18 patients), patients with severe systolic
dysfunction and severe valvular heart disease were excluded in this
study because we inferred that these cardiac conditions per se could
not only strongly affect the patient survival but also influence QRS
voltage and duration. Nevertheless, we could not completely
affirm that there was no selection bias. Second, the 5-year
mortality rates in the present study were relatively lower compared
to those of previous studies on Western ESRD patients [8,30,31],
but they were comparable to those of Japanese patients on HD
[29]. Moreover, a small number of events limited the power of the
statistical analysis in identifying independent predictors of
cardiovascular mortality. Therefore, only 3 factors could be
evaluated at a time in the multivariate analysis to maintain the
statistical power. Third, we analyzed only the ECG taken at the
time of echocardiography. Thus, the possibility of intra-individual
variability could not be completely excluded. However, the lower
day-to-day variability that has been demonstrated for the
measurement of QRS duration could enhance the general use of
voltage-duration product criteria to lessen the influence of day-to-
day variability [39]. Fourth, LVMI by echocardiography was
regarded as the differentiating indicator of LVH in this study. As
mentioned earlier, even though MRI is considered to be the ‘‘gold
standard’’ technique for the assessment of LVM [17], we were
unable to routinely perform MRI in all incident ESRD patients
mainly due to its cost. Finally, follow-up ECG and echocardiog-
raphy were not included for analysis in the present study. It would
be worthwhile to investigate the impact of changes in ECG-LVH
by different criteria on patient outcomes.
Conclusions
This study shows that ECG-LVH based on QRS voltage-
duration product predicts adverse cardiovascular outcomes better
than ECG-LVH by QRS voltage-based criteria in incident HD
patients. Our findings suggest that standard ECG itself may be of
help in risk stratification and in providing therapeutic direction for
the management of these patients.
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